Positive Media Coverage Somewhat Unlikely to Affect MISONIX (NASDAQ:MSON) Stock Price

Press coverage about MISONIX (NASDAQ:MSON) has been trending positive this week, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MISONIX earned a news sentiment score of 0.27 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 46.1661702615691 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

MISONIX (NASDAQ MSON) traded up 1.83% on Monday, reaching $8.35. 1,313 shares of the company traded hands. MISONIX has a 52-week low of $4.85 and a 52-week high of $12.00. The stock has a 50-day moving average of $8.95 and a 200 day moving average of $10.31. The company’s market capitalization is $75.34 million.

TRADEMARK VIOLATION WARNING: “[[title]]” was originally reported by [[site]] and is the property of of [[site]]. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at [[permalink]].

MISONIX Company Profile

Misonix, Inc designs, manufactures, develops and markets minimally invasive therapeutic ultrasonic medical devices. The Company’s products include BoneScalpel surgical system (BoneScalpel), SonaStar Surgical Aspirator (SonaStar), and SonicOne Wound Cleansing and Debridement System (SonicOne). These devices primarily serve the neurosurgery, orthopedic surgery, plastic surgery, wounds, burn and maxillo-facial clinical specialties.